Sponsors › University at Buffalo
University at Buffalo
Every GLP‑1 and incretin trial, approval and scheduled result we hold for University at Buffalo, drawn from ClinicalTrials.gov and Drugs@FDA.
University at Buffalo is an academic or hospital sponsor, not a drug company with 8 trials in the incretin class on file here, across 2 molecules. The programme is split between 1 early-stage trial and 7 in phase 3 or later.
- Molecules
- exenatide · liraglutide
- Trials on file
- 8
- Active trials
- 0
- Results scheduled
- 0
- Approved FDA submissions
- 0
Trials on file
All 8 incretin trials recorded for this sponsor, active first.
| Drug | Trial | Status | Phase | Participants |
|---|---|---|---|---|
| liraglutide | Liraglutide In Overweight Patients With Type 1 Diabetes NCT01753362 | Completed | P3 | 84 |
| liraglutide | Liraglutide in the Treatment of Type 1 Diabetes Mellitus NCT01722266 | Completed | P3 | 72 |
| liraglutide | Liraglutide in Type 1 Diabetes NCT01722240 | Completed | P3 | 69 |
| liraglutide | Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes NCT02518945 | Completed | P3 | 26 |
| exenatide | Exeantide in Type 2 Diabetes on Insulin NCT01154933 | Completed | P2 | 24 |
| exenatide | GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes NCT03029351 | Terminated | P4 | 15 |
| liraglutide | Liraglutide in Adolescents With Type 1 Diabetes NCT02516657 | Completed | P3 | 5 |
| liraglutide | Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes NCT01722227 | Withdrawn | P3 | — |